1. Home
  2. INCY vs SGI Comparison

INCY vs SGI Comparison

Compare INCY & SGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • SGI
  • Stock Information
  • Founded
  • INCY 1991
  • SGI 1846
  • Country
  • INCY United States
  • SGI United States
  • Employees
  • INCY N/A
  • SGI N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • SGI Home Furnishings
  • Sector
  • INCY Health Care
  • SGI Consumer Discretionary
  • Exchange
  • INCY Nasdaq
  • SGI Nasdaq
  • Market Cap
  • INCY 17.0B
  • SGI 17.4B
  • IPO Year
  • INCY 1993
  • SGI N/A
  • Fundamental
  • Price
  • INCY $105.82
  • SGI $89.20
  • Analyst Decision
  • INCY Buy
  • SGI Strong Buy
  • Analyst Count
  • INCY 19
  • SGI 6
  • Target Price
  • INCY $89.19
  • SGI $87.17
  • AVG Volume (30 Days)
  • INCY 2.7M
  • SGI 2.0M
  • Earning Date
  • INCY 10-28-2025
  • SGI 11-06-2025
  • Dividend Yield
  • INCY N/A
  • SGI 0.67%
  • EPS Growth
  • INCY 3878.02
  • SGI N/A
  • EPS
  • INCY 5.90
  • SGI 1.58
  • Revenue
  • INCY $4,813,105,000.00
  • SGI $6,816,000,000.00
  • Revenue This Year
  • INCY $19.33
  • SGI $52.79
  • Revenue Next Year
  • INCY $10.47
  • SGI $5.73
  • P/E Ratio
  • INCY $17.83
  • SGI $56.39
  • Revenue Growth
  • INCY 18.09
  • SGI 39.29
  • 52 Week Low
  • INCY $53.56
  • SGI $49.23
  • 52 Week High
  • INCY $106.47
  • SGI $89.71
  • Technical
  • Relative Strength Index (RSI)
  • INCY 81.21
  • SGI 66.39
  • Support Level
  • INCY $91.16
  • SGI $78.01
  • Resistance Level
  • INCY $106.47
  • SGI $84.26
  • Average True Range (ATR)
  • INCY 4.17
  • SGI 2.17
  • MACD
  • INCY 1.69
  • SGI 0.14
  • Stochastic Oscillator
  • INCY 97.08
  • SGI 95.65

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About SGI Somnigroup International Inc. Common Stock

Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.

Share on Social Networks: